Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

LABORATORY CORPORATION OF AMERICA HOLDINGS

(LH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Laboratory of America : Labcorp Says COVID-19 PCR Test Kit Receives FDA Emergency Use Authorization for Ages 2-17

05/13/2021 | 09:20am EDT


© MT Newswires 2021
All news about LABORATORY CORPORATION OF AMERICA HOLDINGS
06/24GENFIT  : presents new NIS4 data in NASH at the International Liver Congress and..
AQ
06/22LABORATORY OF AMERICA  : Labcorp Deploys Molecular Loop's Research Sequencing Pa..
MT
06/22LABORATORY OF AMERICA  : Labcorp Adopts Molecular Loop SARS-CoV-2 Research Seque..
PR
06/14LABORATORY OF AMERICA  : OmniSeq Launch Genomic, Immune Profiling Test OmniSeq I..
MT
06/14LABORATORY OF AMERICA  : Labcorp And OmniSeq Launch INSIGHT℠, Next-Generat..
PR
06/09Labcorp Launches COVID-19 At-Home Test Kit at Walgreens
MT
06/08LABORATORY OF AMERICA  : Pixel by Labcorp® COVID-19 PCR Test Home Collection Kit..
BU
06/07CORRECTION : Mizuho Securities Maintains Laboratory Corp of America Holdings PT ..
MT
06/07LABORATORY OF AMERICA  : Mizuho Securities Adjusts Laboratory Corp of America Ho..
MT
06/03LABORATORY OF AMERICA  : Labcorp to Introduce Combined Oncology Offering at 2021..
AQ
More news
Financials (USD)
Sales 2021 14 564 M - -
Net income 2021 1 876 M - -
Net Debt 2021 3 548 M - -
P/E ratio 2021 13,8x
Yield 2021 -
Capitalization 25 874 M 25 874 M -
EV / Sales 2021 2,02x
EV / Sales 2022 2,12x
Nbr of Employees 68 780
Free-Float 99,4%
Chart LABORATORY CORPORATION OF AMERICA HOLDINGS
Duration : Period :
Laboratory Corporation of America Holdings Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LABORATORY CORPORATION OF AMERICA HOLDINGS
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 17
Last Close Price 264,99 $
Average target price 298,31 $
Spread / Average Target 12,6%
EPS Revisions
Managers and Directors
NameTitle
Adam H. Schechter Chairman, President & Chief Executive Officer
Glenn Andrew Eisenberg Chief Financial Officer & Executive Vice President
Lance V. Berberian Chief Information & Technology Officer & EVP
Brian J. Caveney Chief Medical Officer, EVP & President-Diagnostics
Stephen M. Anderson Chief Scientific Officer-Covance & Senior VP
Sector and Competitors